{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:09:38Z","timestamp":1787065778252,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"National Research Development and Innovation Office","doi-asserted-by":"publisher","award":["2020-1.1.6-J\\u00D6V\\u0150-2021-00003"],"award-info":[{"award-number":["2020-1.1.6-J\\u00D6V\\u0150-2021-00003"]}],"id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcf.2025.08.012","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T02:54:46Z","timestamp":1756004086000},"page":"1166-1172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of long-term elexacaftor\/tezacaftor\/ivacaftor therapy on oxidative stress in cystic fibrosis: early insights"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9136-3265","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"\u00d6rl\u0151s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0067-5166","authenticated-orcid":false,"given":"Imre","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"P\u00e1ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6791-0901","authenticated-orcid":false,"given":"Adrien","family":"Hal\u00e1sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Antus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.08.012_bib0001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.biocel.2014.03.006","article-title":"Redox balance in cystic fibrosis","volume":"52","author":"Ziady","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"issue":"16","key":"10.1016\/j.jcf.2025.08.012_bib0002","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.3390\/molecules27165324","article-title":"Cystic Fibrosis and oxidative stress: the role of CFTR","volume":"27","author":"Moliteo","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jcf.2025.08.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101436","article-title":"Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: a systematic review and meta-analysis","volume":"32","author":"Causer","year":"2020","journal-title":"Redox Biol"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.012_bib0004","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00408-015-9739-1","article-title":"Comparison of airway and systemic malondialdehyde levels for assessment of oxidative stress in cystic fibrosis","volume":"193","author":"Antus","year":"2015","journal-title":"Lung"},{"issue":"1-3","key":"10.1016\/j.jcf.2025.08.012_bib0005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2005.12.087","article-title":"Oxidant and antioxidant balance in the airways and airway diseases","volume":"533","author":"Rahman","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.jcf.2025.08.012_bib0006","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1164\/rccm.200212-1479SO","article-title":"Superoxide dismutases in the lung and human lung diseases","volume":"167","author":"Kinnula","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"5-6","key":"10.1016\/j.jcf.2025.08.012_bib0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000046685","article-title":"Antioxidant status in patients with cystic fibrosis","volume":"44","author":"Madarasi","year":"2000","journal-title":"Ann Nutr Metab"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.012_bib0008","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/ajcn\/61.4.843","article-title":"Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis","volume":"61","author":"Portal","year":"1995","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.jcf.2025.08.012_bib0009","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1183\/09031936.98.11020377","article-title":"myeloperoxidase and hydrogen peroxide in cystic fibrosis","volume":"11","author":"Worlitzsch","year":"1998","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jcf.2025.08.012_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0009-8981(82)90045-6","article-title":"Altered peroxide metabolism in erythrocytes from children with cystic fibrosis","volume":"125","author":"Matkovics","year":"1982","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.012_bib0011","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40272-022-00509-y","article-title":"An update on CFTR modulators as new therapies for cystic fibrosis","volume":"24","author":"King","year":"2022","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jcf.2025.08.012_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221098136","article-title":"New drugs in cystic fibrosis: what has changed in the last decade?","volume":"13","author":"Roda","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"issue":"10212","key":"10.1016\/j.jcf.2025.08.012_bib0013","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2025.08.012_bib0014","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"VX17-445-102 Study group. Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.012_bib0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.jcf.2025.08.012_bib0016","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jcf.2025.08.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.08.012_bib0018","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of Cystic Fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"12","key":"10.1016\/j.jcf.2025.08.012_bib0019","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1164\/rccm.201003-0451OC","article-title":"Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: A longitudinal study","volume":"182","author":"Antus","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.012_bib0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000358099","article-title":"Sputum eicosanoid profiling in exacerbations of chronic obstructive pulmonary disease","volume":"87","author":"Drozdovszky","year":"2014","journal-title":"Respiration"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.012_bib0021","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/15412555.2018.1535581","article-title":"Monitoring antioxidant enzyme activity during exacerbations of chronic obstructive pulmonary disease","volume":"15","author":"Antus","year":"2018","journal-title":"COPD"},{"issue":"10","key":"10.1016\/j.jcf.2025.08.012_bib0022","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00011-012-0508-9","article-title":"Exhaled breath condensate pH in patients with cystic fibrosis","volume":"61","author":"Antus","year":"2012","journal-title":"Inflamm Res"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.012_bib0023","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/thorax.58.4.294","article-title":"Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD","volume":"58","author":"Biernacki","year":"2003","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.012_bib0024","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/0884533614530170","article-title":"Relationship between fat-soluble vitamin supplementation and blood concentrations in adolescent and adult patients with cystic fibrosis","volume":"29","author":"Siwamogsatham","year":"2014","journal-title":"Nutr Clin Pr."},{"key":"10.1016\/j.jcf.2025.08.012_bib0025","doi-asserted-by":"crossref","unstructured":"Brown RK, McBurney A, Lunec J, Kelly FJ. Free Radic Biol Med. 1995 Apr;18(4):801-6.","DOI":"10.1016\/0891-5849(94)00172-G"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.012_bib0026","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jcf.2017.02.007","article-title":"Peripheral muscle abnormalities in cystic fibrosis: etiology, clinical implications and response to therapeutic interventions","volume":"16","author":"Gruet","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.08.012_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2930434","article-title":"Oxidative stress markers in sputum","volume":"2016","author":"Antus","year":"2016","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.012_bib0028","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The impact of highly effective modulator therapy on cystic fibrosis microbiology and inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.012_bib0029","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor \/Tezacaftor \/ Ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.08.012_bib0030","article-title":"The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: A systematic review","volume":"15","author":"Salazar-Barragan","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.012_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor - Tezacaftor - Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:20Z","timestamp":1779953720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1569199325015723"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of long-term elexacaftor\/tezacaftor\/ivacaftor therapy on oxidative stress in cystic fibrosis: early insights","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}